{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:25:43Z","timestamp":1761744343521},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,5,18]],"date-time":"2016-05-18T00:00:00Z","timestamp":1463529600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s00345-016-1853-z","type":"journal-article","created":{"date-parts":[[2016,5,18]],"date-time":"2016-05-18T07:11:52Z","timestamp":1463555512000},"page":"105-111","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer"],"prefix":"10.1007","volume":"35","author":[{"given":"Nirmish","family":"Singla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Q.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niccolo M.","family":"Passoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Meissner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,18]]},"reference":[{"key":"1853_CR1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","volume":"65","author":"RL Siegel","year":"2015","unstructured":"Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5","journal-title":"CA Cancer J Clin"},{"key":"1853_CR2","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","volume":"64","author":"M Babjuk","year":"2013","unstructured":"Babjuk M, Burger M, Zigeuner R et al (2013) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64:639","journal-title":"Eur Urol"},{"key":"1853_CR3","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","volume":"67","author":"RF Han","year":"2006","unstructured":"Han RF, Pan JG (2006) Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 67:1216","journal-title":"Urology"},{"key":"1853_CR4","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"PU Malmstrom","year":"2009","unstructured":"Malmstrom PU, Sylvester RJ, Crawford DE et al (2009) An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 56:247","journal-title":"Eur Urol"},{"key":"1853_CR5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI114434","volume":"85","author":"LR Kavoussi","year":"1990","unstructured":"Kavoussi LR, Brown EJ, Ritchey JK et al (1990) Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest 85:62","journal-title":"J Clin Invest"},{"key":"1853_CR6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1172\/JCI116202","volume":"91","author":"K Kuroda","year":"1993","unstructured":"Kuroda K, Brown EJ, Telle WB et al (1993) Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells. J Clin Invest 91:69","journal-title":"J Clin Invest"},{"key":"1853_CR7","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/01.ju.0000073852.24341.4a","volume":"170","author":"A Bohle","year":"2003","unstructured":"Bohle A, Brandau S (2003) Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 170:964","journal-title":"J Urol"},{"key":"1853_CR8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.biopha.2007.05.004","volume":"61","author":"S Brandau","year":"2007","unstructured":"Brandau S, Suttmann H (2007) Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother 61:299","journal-title":"Biomed Pharmacother"},{"key":"1853_CR9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1464-410X.2011.10318.x","volume":"109","author":"E Scosyrev","year":"2012","unstructured":"Scosyrev E, Golijanin D, Wu G et al (2012) The burden of bladder cancer in men and women: analysis of the years of life lost. BJU Int 109:57","journal-title":"BJU Int"},{"key":"1853_CR10","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2011.1142","volume":"306","author":"ND Freedman","year":"2011","unstructured":"Freedman ND, Silverman DT, Hollenbeck AR et al (2011) Association between smoking and risk of bladder cancer among men and women. Jama 306:737","journal-title":"Jama"},{"key":"1853_CR11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/0003-4819-136-2-200201150-00016","volume":"136","author":"M Hayden","year":"2002","unstructured":"Hayden M, Pignone M, Phillips C et al (2002) Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 136:161","journal-title":"Ann Intern Med"},{"key":"1853_CR12","first-page":"CD004816","volume":"1","author":"F Taylor","year":"2013","unstructured":"Taylor F, Huffman MD, Macedo AF et al (2013) Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 1:CD004816","journal-title":"Cochrane Database Syst Rev"},{"key":"1853_CR13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0049-3848(03)00379-7","volume":"110","author":"JR Vane","year":"2003","unstructured":"Vane JR, Botting RM (2003) The mechanism of action of aspirin. Thromb Res 110:255","journal-title":"Thromb Res"},{"key":"1853_CR14","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nri1839","volume":"6","author":"J Greenwood","year":"2006","unstructured":"Greenwood J, Steinman L, Zamvil SS (2006) Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 6:358","journal-title":"Nat Rev Immunol"},{"key":"1853_CR15","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1194\/jlr.M010876","volume":"52","author":"TT Tang","year":"2011","unstructured":"Tang TT, Song Y, Ding YJ et al (2011) Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis. J Lipid Res 52:1023","journal-title":"J Lipid Res"},{"key":"1853_CR16","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.juro.2009.06.026","volume":"182","author":"SA Boorjian","year":"2009","unstructured":"Boorjian SA, Berglund RK, Maschino AC et al (2009) Fibrin clot inhibitor medication and efficacy of bacillus Calmette-Guerin for bladder urothelial cancer. J Urol 182:1306","journal-title":"J Urol"},{"key":"1853_CR17","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1464-410X.2008.08123.x","volume":"103","author":"JR Gee","year":"2009","unstructured":"Gee JR, Jarrard DF, Bruskewitz RC et al (2009) Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guerin. BJU Int 103:736","journal-title":"BJU Int"},{"key":"1853_CR18","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.urology.2012.09.065","volume":"81","author":"MJ Lipsky","year":"2013","unstructured":"Lipsky MJ, Badalato GM, Motamedinia P et al (2013) The effect of fibrin clot inhibitors on the immunomodulatory efficacy of Bacillus Calmette-Guerin therapy for non-muscle-invasive bladder cancer. Urology 81:1273","journal-title":"Urology"},{"key":"1853_CR19","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.juro.2008.06.034","volume":"180","author":"RK Berglund","year":"2008","unstructured":"Berglund RK, Savage CJ, Vora KC et al (2008) An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder. J Urol 180:1297","journal-title":"J Urol"},{"key":"1853_CR20","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.1111\/bju.12150","volume":"112","author":"JJ Crivelli","year":"2013","unstructured":"Crivelli JJ, Xylinas E, Kluth LA et al (2013) Effect of statin use on outcomes of non-muscle-invasive bladder cancer. BJU Int 112:E4","journal-title":"BJU Int"},{"key":"1853_CR21","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1056\/NEJMc062714","volume":"355","author":"P Hoffmann","year":"2006","unstructured":"Hoffmann P, Roumeguere T, Schulman C et al (2006) Use of statins and outcome of BCG treatment for bladder cancer. N Engl J Med 355:2705","journal-title":"N Engl J Med"},{"key":"1853_CR22","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1056\/NEJMc070117","volume":"356","author":"AM Kamat","year":"2007","unstructured":"Kamat AM, Wu X (2007) Statins and the effect of BCG on bladder cancer. N Engl J Med 356:1276 (author reply 1276)","journal-title":"N Engl J Med"},{"key":"1853_CR23","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jamcollsurg.2009.04.014","volume":"209","author":"TA Skolarus","year":"2009","unstructured":"Skolarus TA, Lee EW, Virgo KS et al (2009) Intravesical bacille Calmette-Guerin therapy for non-muscle-invasive bladder cancer: effects of concurrent statin therapy. J Am Coll Surg 209:248","journal-title":"J Am Coll Surg"},{"key":"1853_CR24","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm DL, Blumenstein BA, Crissman JD et al (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163:1124","journal-title":"J Urol"},{"key":"1853_CR25","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/annonc\/mds113","volume":"23","author":"C Bosetti","year":"2012","unstructured":"Bosetti C, Rosato V, Gallus S et al (2012) Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 23:1403","journal-title":"Ann Oncol"},{"key":"1853_CR26","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nrurol.2011.219","volume":"9","author":"C Bosetti","year":"2012","unstructured":"Bosetti C, Rosato V, Gallus S et al (2012) Aspirin and urologic cancer risk: an update. Nat Rev Urol 9:102","journal-title":"Nat Rev Urol"},{"key":"1853_CR27","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/1756287215599695","volume":"7","author":"V Pagliarulo","year":"2015","unstructured":"Pagliarulo V, Ancona P, Martines I et al (2015) Celecoxib for the prevention of nonmuscle invasive bladder cancer: results from a matched control study. Ther Adv Urol 7:303","journal-title":"Ther Adv Urol"},{"key":"1853_CR28","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12885-015-1152-x","volume":"15","author":"A Pastore","year":"2015","unstructured":"Pastore A, Palleschi G, Fuschi A et al (2015) Can daily intake of aspirin and\/or statins influence the behavior of non-muscle invasive bladder cancer? A retrospective study on a cohort of patients undergoing transurethral bladder resection. BMC Cancer 15:120","journal-title":"BMC Cancer"},{"key":"1853_CR29","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(09)60243-9","volume":"373","author":"PC Elwood","year":"2009","unstructured":"Elwood PC, Gallagher AM, Duthie GG et al (2009) Aspirin, salicylates, and cancer. Lancet 373:1301","journal-title":"Lancet"},{"key":"1853_CR30","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/bjc.2011.289","volume":"105","author":"RE Langley","year":"2011","unstructured":"Langley RE, Burdett S, Tierney JF et al (2011) Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br J Cancer 105:1107","journal-title":"Br J Cancer"},{"key":"1853_CR31","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/aje\/kwq437","volume":"173","author":"SE Daugherty","year":"2011","unstructured":"Daugherty SE, Pfeiffer RM, Sigurdson AJ et al (2011) Nonsteroidal antiinflammatory drugs and bladder cancer: a pooled analysis. Am J Epidemiol 173:721","journal-title":"Am J Epidemiol"},{"key":"1853_CR32","doi-asserted-by":"crossref","first-page":"e70008","DOI":"10.1371\/journal.pone.0070008","volume":"8","author":"H Zhang","year":"2013","unstructured":"Zhang H, Jiang D, Li X (2013) Use of nonsteroidal anti-inflammatory drugs and bladder cancer risk: a meta-analysis of epidemiologic studies. PLoS One 8:e70008","journal-title":"PLoS One"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-016-1853-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-016-1853-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-016-1853-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-016-1853-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T09:46:23Z","timestamp":1559036783000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-016-1853-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,18]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["1853"],"URL":"https:\/\/doi.org\/10.1007\/s00345-016-1853-z","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,18]]}}}